8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2025
Open accessThe DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“physical activity plays an indispensable role”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [53]
In the citing paper
“Evidence-based dietary management is the cornerstone of T2DM prevention and control, as it can effectively improve glycemic control and even achieve disease remission (2).”
In the citing paper
“Those with obesity who have engaged in some form of calorie or dietary restriction have a higher likelihood of developing nutritional deficiencies [53,98,99,130,131]”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [53]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationEffects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citation2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Self-citationBariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Research works printed but not linked: 2
- Steven, 2016, Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes Care 2016;39:808–815, Diabetes Care, 41, 1321
- American Medical Association . Person-First Language for Obesity H-440.821. Accessed 21 August 2024. Available from https://policysearch.ama-assn.org/policyfinder/detail/obesity?uri=%2FAMADoc%2FHOD.xml-H-440.821.xml
Cited by
Items 201–269 of 269
Скрипник, І. М., Ron, Y., SOKOLOVA, L. K., Bondarenko, O. O., Maslova, G., & Filippova, O. (2026) · Family medicine European practices · doi:10.30841/2786-720x.1.2026.353747
Current trends in pharmacotherapy of overweight and obesity
Ürgeová, A., & Kozárová, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.099
Warmbrunn, M. V., Yang, L., Biswas, R. K., Ryan, C. P., Harper, A., Belsky, D. W., Fiorito, G., & Fontana, L. (2026) · Diabetes Care · doi:10.2337/dc25-1911 · Cited by 1
Wannachalee, T., Anthanont, P., Sirisreetreerux, S., Nayak, G., Chumchujan, W., Iamsudjai, Y., & Buranapin, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70701
Darlenski, R., Mihaylova, V., Manuelyan, K., Zheleva, D., Bogdanov, G., Bogdanov, I., Kundurzhiev, T., Gateva, P., Fogelholm, M., Raben, A., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1796607
Gallwitz, B., Aberle, J., Birkenfeld, A. L., Kellerer, M., Klein, H. H., Landgraf, R., Müller‐Wieland, D., Müssig, K., Nauck, M. A., Siegel, E. G., et al. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01469-4
Evaluate the effect of sleeve gastrectomy on serum lipids and serum calcium
Ali, S. A. E.-S., Shemy, G. G., & Mohammed, M. S. (2026) · Al-Azhar Assiut Medical Journal · doi:10.4103/azmj.azmj_78_25
Alawadi, F., Abdelgadir, E., Hassoun, A. A. K., Abusnana, S., Afandi, B. O., Aldahmani, K. M., Alkaabi, J., Bashier, A. M., Bayado, F., Belaila, B. A. B., et al. (2026) · Dubai Diabetes and Endocrinology Journal · doi:10.18502/ddej.v32i1.21067
Cao, X., Shen, G., & Sun, T. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s598731 · Cited by 2
“10,68 Future studies should conduct multicenter, prospective, large-scale cohort studies incorporating longitudinal body composition tracking data and fully accounting for the interactions between muscle and fat to further elucidate the influence of body composition on T2DM development.”
Ji, Y. (2026) · cIRcle (University of British Columbia)
Retana, R. S., Chamorro, Á. Q., Marte, A. M. Z., Garg, A., Verma, A., Modesto, A. D. Á. M., Braga, A. G. O., Trisolini, B. J. V., Gajbhiye, D. I., Kortan, E. K., et al. (2026) · Principles and Practice of Clinical Research Journal · doi:10.21801/ppcrj.2025.114.9
B-Group Vitamins in Internal Medicine, Gynaecology and Neurology: A Comprehensive Clinical Review
Pršo, A.-M. L., Pejić, M. K., Milotić, D. M., Matijaca, A., Matijaca, H., Marton, U., Sruk, A., & Gojo-Tomic, N. (2026) · Biochemistry · doi:10.5772/intechopen.1014859 · Cited by 1
Wiesmüller, F., Kreiner, K., Reinisch, V., Hoffmann, F., Schreier, G., & Hayn, D. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1720149
“The recommended PA levels are in accordance with the WHO recommendation for physical activity (6–8).”
Sustained Approaches to Prevent Recurrence and Support Ongoing Diabetes Health
Ambawatiya, A., Goyal, K., Dahiya, R., Hyderi, Z., Singh, L. K., Srivastava, J., Kumar, N., & Abubakar, M. (2026) · Springer eBooks · doi:10.1007/978-981-95-8946-3_15
Fraser, K. T., Sullivan, J., Toppenberg, L., Masseo, P., Tsega, A., Prokopow, L., Willingham, C., & Cohen, N. (2026) · BMC Public Health · doi:10.1186/s12889-026-27708-3
“There is also evidence that glucagon-like peptide-1 receptor agonists (GLP-1s) can be effective in diabetes treatment [10–12], and clinical guidance recommends both lifestyle modifications and GLP-1 use for treatment [13, 14].”
Pashaeimofrad, A., Schriever, C. A., Rosella, T., & Carmichael, A. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag128
Mapping research trends in shared decision-making for type 2 diabetes mellitus: a bibliometric study
Castillo, C. M. S., García-Mera, C., Hernández-Leal, M. J., & Manterola, C. (2026) · Frontiers in Health Services · doi:10.3389/frhs.2026.1799382
“Studies show it often leads to bigger, longer-lasting weight loss and more frequent diabetes remission than lifestyle changes alone (41).”
Santos, G. G. L., & Vásquez, H. A. (2026) · Revista Multidisciplinar Epistemología de las Ciencias · doi:10.71112/gra9k997
Floch, N. R. (2026) · Springer eBooks · doi:10.1007/978-3-032-21069-2_15
Chomko, M. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch05
Yin, Y., Ma, J. H., Liu, D., Duan, W., Cheng, Z., Jiang, H. X., Zhang, Y., Wu, G., Zhuang, H., Gu, W., et al. (2026) · Med · doi:10.1016/j.medj.2026.101183
Diabetes and Weight Management
Perry, M. L. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch13 · Cited by 1
Correia, P. E., Teixeira, P. P., Martins, B. A. E. T., Porepp, O. D. S. C., Kunzler, L. B., da Natividade, G. R., Ferrari, G. T., Spiazzi, B. F., Colpani, V., & Gerchman, F. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103411
Chen, L., Li, A., Chen, W., & Zhou, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1768569
“Drawing on the iCARDIO 2025 Guidelines (45) and the ADA Standards of Care in Diabetes (46), we translated the WHtR-BFP nine-grid assessment into a practical tiered management framework.”
Metabolic Surgery: Outcomes and Choice
Aminian, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_10
Zhao, C. (2026) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2026.39.9.243.1
Machado, A. V. (2025) · RIUnB Institutional Repository (University of Brasília)
Donaldson, A. T., Oddi, B. T., Dusi, J., Foster, B. F., & Federico, M. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261463126
Sun, Y., Li, X., & Xu, L. (2026) · Endocrine · doi:10.1007/s12020-026-04699-0
“…of this study not only align with the ADA guidelines principle that “gly-cemic management requires balancing target achievement with stability”, [22 ] but also support that the combination of GLP-1RA with basal insulin reduces glycemic variability, potentially offering cardiovascular and…”
Miličević, T., Cvitković, I., Volčanšek, Š., Katsiki, N., Mikhailidis, D. P., Patoulias, D., & Muzurović, E. M. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2706660
Hu, R., Luo, X., He, C., Cui, X., Yuan, P., He, Q., 董, 梅., Du, J., & Zhang, X. (2026) · Journal of Clinical Nursing · doi:10.1111/jocn.70457
Gutiérrez-Barros, G. A., Morales-Morales, M. V., Morales-Donado, G. M., Bartos, A. F. A., Gutiérrez, C. D. R., Jiménez, M. F. B., Cervantes, S. A. L., Mancipe, V. A. B., Ortega, L. M. A., Nieves, S. N., et al. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.147020
Metabolic Syndrome: Redefine and Expand Its Reach, Yet Preserve Its Clinical Value
Saad, M. J. A., Santos, A., Geloneze, B., & Velloso, L. A. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.07.008 · Cited by 1
HbA1c Management of Endocrine Disorders and the Pharmacist's Role: Diabetes
Krass, I., Hoti, K., Khalil, H., Ludington, J. E., & Namara, K. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26472-6.00021-8
Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Mohamed, M. R., Abdallfatah, A., Elsekhary, A., El‐Nemr, A. F., Eladawi, S., Maihoub, O., Abdulhay, H., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70275
Doğan, İ., Deniz, S. S., Bartın, M. K., Sönmez, E., Delice, M. C., Coban, S., & Çelik, S. (2026) · Medicina · doi:10.3390/medicina62081450
“Lifestyle modification remains the cornerstone of obesity management and is recommended as first-line therapy by all major international clinical practice guidelines [1,2,4,6–8].”
de Assis, D. C. M., Coelho, F. M. M., de Melo, P. M., & dos Santos, D. W. (2026) · Research Society and Development · doi:10.33448/rsd-v15i7.51433
Tam, K., & Lund, H. (2026) · Springer eBooks · doi:10.1007/978-3-031-90919-1_22-1
Du, Y., Sarganas, G., Gaertner, B., Buchmann, M., Fuchs, J., Neuhauser, H. K., & Heidemann, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71184
“Apart from medications, self-management of health behaviours is an essential component of comprehensive diabetes care and serves as the basic measure for the therapy of T2D [19–21].”
Trastulli, S., Parisi, A., Grandone, I., Fontana, L., Desiderio, J., Giannarelli, D., Cirocchi, R., Luca, G., Palazzi, M., Fatati, G., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03021-z
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
Chen, Q.-X., Xiao-yu, Z., Wu, Q., Xie, J.-J., Xu, Y., Teng, F., & Guo, M. (2026) · Endocrine · doi:10.1007/s12020-026-04757-7
“In patients with T2DM or obesity who are normotensive at baseline, the primary treatment goal is often to correct metabolic abnormalities, reduce weight, and protect target organs rather than to further lower BP [ 73 ].”
Singh, B., Yaylaci, F., Ali, H. M., Baweja, R., Suarez, M. L. G., & Baweja, R. K. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122407
Olaniyi, A. O., Gogineni, K. K., Olaniyi, H., Sabir, H., Eboigbe, G. A., Yerima, S. R., & Gabriels, N. (2026) · Cureus · doi:10.7759/cureus.114962
Liu, F., Zhu, X., Leng, H., & Chen, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1930328
Obesity: Beyond Weight Loss to Comprehensive Disease Management
Bashir, M. I. (2026) · Pakistan BioMedical Journal · doi:10.54393/pbmj.v9i8.1407
Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Bahnasy, S., Eladawi, S., Abdelaziz, M., Iyad, K., Kandil, A. H., Zinhom, K., Reyad, M., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70313
“SMBS and IFSO recommend metabolic surgery for BMI > 35 kg/m 2 and consider it for BMI 30–34.9 kg/m 2 with metabolic disease, consistent with ADA guidance [40, 41].”
InfluentialBodner, E., Gentz, A., Wiencke, K., Mehl, N., & Schlögl, H. (2026) · Obesity Reviews · doi:10.1111/obr.70221
Güven, D. Y., & Aksoy, E. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1866634
Diab, A. R., Chang, T. H. W., Diab, O., & Kheir, M. M. (2026) · Hip International · doi:10.1177/11207000261476202
Yao, J., Tai, E. S., Sim, X., Müller‐Riemenschneider, F., & van Dam, R. M. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156782
Economic evaluations of antiobesity medications: A systematic literature review
Jurković, M., Fajkić, A., Faour, A. K., Momčilović, M., Turčić, P., & Belančić, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70825
Practical use of GLP-1-based medications in obesity clinics
Jethwani, P. D., Hallock, R., & Griebeler, M. L. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.011
Latt, T. S., Aye, T. T., Ko, K., Than, K. S., Kalra, S., Kapoor, N., Myint, T., Win, S. S., Khin, H. H., Hlaing, N. N., et al. (2026) · Cureus · doi:10.7759/cureus.116808
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Individualized exercise for body recomposition and multidimensional health in type 2 diabetes
Vito, G. D., & Martino, G. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.09.078
Bangun, H. A., Girsang, E., Siregar, S. D., Ginting, R., Manalu, P., Tarigan, Y. G., & Kachingwe, B. H. (2026) · Journal of Health Research · doi:10.56808/2586-940x.1217
Wang, Y., Liu, Z., Wang, S., Lv, C., El-Seedi, H. R., Khalifa, S. A. M., & Wang, H. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70351
“The thematic transition is also clinically coherent with diabetes recommendations integrating individualized glycemic management [37], cardiovascular risk reduction [38], kidney protection [39] and weight management [40].”
ชาลี, ย. (2026) · Journal of Khon Kaen Provincial Health Office
Локшин, В. Н., Бекбосынова, М. С., Гребенникова, Г. А., Дурманова, А. К., Макалкина, Л. Г., Nersesov, A., Ospanov, O. B., Raissova, A., & Шарман, А. Т. (2026) · Репродуктивная медицина (Центральная Азия) · doi:10.37800/rm.3.2026.881
Chua, C. H., Chong, W. L., & Huri, H. Z. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209050
“Existing recommendations often emphasise the addition of weight-reducing non-insulin agents, but provide less detail on how insulin regimens themselves should be modified [12].”
Wang, W., Kilpatrick, M., Robertson, I. K., & Murfet, G. O. (2026) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph23101318
Saeed, U., Uppal, M. R., Uppal, R., Szepesváry, Z. J., & Piracha, Z. Z. (2026) · Diseases · doi:10.3390/diseases14100379
“This integrated approach is consistent with contemporary diabetes, CKD, cardiovascular-risk, lipid, and MASLD guidance [10,11,15,18,23,24,28–30].”
Boye, K. S., Cutts, K. N., Zhao, Y., Steere, E., & Gelhorn, H. L. (2026) · Patient · doi:10.1007/s40271-026-00847-w
El Health Advisor como facilitador del cambio conductual en adultos con obesidad
Cepeda, C. E. (2025) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v9i4.25942
Poboży, M., Rulkiewicz, A., Lisik, W., Stojčev, Z., Filipiak-Rokicka, E., Pilchowska, I., & Domienik‐Karłowicz, J. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1920503
“The findings support a preventive strategy focused on verifying elevated blood pressure, evaluating glycaemic and cardiovascular risk when clinically justified, implementing evidence-based weight management, and promoting non-discriminatory workplace health initiatives (16, 17, 23, 24, 27, 29, 34).”
Jun, J. E., Ryu, H. J., Hwang, Y., Ahn, K. J., Chung, H. Y., Lee, S. J., Jeong, I., & Choi, S. I. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71455
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., Garg, R., Khunti, K., Kushner, R. F., Lal, R., Lingvay, I., Matfin, G., Pandya, N., Pekas, E. J., Pilla, S. J., Polsky, S., Segal, A. R., Seley, J. J., Stanton, R. C., & Bannuru, R. R.
- ORCID
- ElSayed, Nuha A.
- McCoy, Rozalina G.
- Aleppo, Grazia
- Balapattabi, Kirthikaa
- Beverly, Elizabeth A.
- Briggs Early, Kathaleen
- Bruemmer, Dennis
- Echouffo-Tcheugui, Justin B.
- Ekhlaspour, Laya
- Garg, Rajesh
- Khunti, Kamlesh
- Kushner, Robert F.
- Lal, Rayhan
- Lingvay, Ildiko
- Pandya, Naushira
- Pekas, Elizabeth J.
- Pilla, Scott J.
- Polsky, Sarit
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Bannuru, Raveendhara R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2024-12-09
- Volume
- 48
- Issue
- Supplement_1
- Pages
- S167-S180
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC11635032
- OpenAlex
- W4405187634
- Cited by
- 236
- References
- 157
- Citations by year
- 2026: 102 · 2025: 119 · 2024: 9
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, weight management, type 2 diabetes, diabetes prevention, diabetes treatment, clinical guidelines
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Obesity, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.